European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.

Nonparametric Estimation from Incomplete Observations

1958 • 7,673 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

WHO Handbook for Reporting Results of Cancer Treatment

1982 • 2,214 citations

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

2002 • 1,346 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1991 • 444 citations

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

1992 • 443 citations

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1998 • 176 citations

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.

1991 • 165 citations

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

1987 • 155 citations

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.

1996 • 149 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.

1988 • 131 citations

Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule

1999 • 114 citations

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.

1994 • 88 citations

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.

1992 • 67 citations

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

1997 • 63 citations

Small-cell lung cancer.

2001 • 59 citations

Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study

2001 • 49 citations

Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base

1993 • 44 citations

Single agent oral topotecan (OT) as first-line treatment for patients (pts) with extensive disease (ED) small cell lung cancer (SCLC) ineligible for standard therapy: A phase II study

2000 • 33 citations

Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC lung cancer cooperative group

1993 • 29 citations

Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung Cancer

1988 • 28 citations

A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer

2000 • 27 citations

Treatment of relapsed small cell lung cancer

2001 • 23 citations

Phase II study of oral topotecan (T) with cisplatin (C) in advanced, non-resectable NSCLC. A promising combination

2000 • 4 citations